If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Wockhardt did not reply to a detailed e-mail questionnaire sent by Business Standard.
According to industry sources, the Shendra factory was also inspected by the Medicines and Healthcare Products Regulatory Agency of Britain and the Irish regulator, a few months earlier, getting approval. Now, the observers expect a US clearance, too.
The Mumbai-based drug maker has been facing trouble in developed markets since early 2013, when its Waluj (Maharashtra) facility first came under the US FDA scanner, following manufacturing violations. Since then, many other of its domestic facilities have faced enforcements in the US and Europe.
Apart from Waluj and Chikalthana, barred from supplying to the US, its factory in Daman came under the scanner of MHRA.
Last September, the Wockhardt management had indicated it might shift US-bound products from the troubled Waluj unit to its plant at Shendra.
Correction offers good value in pharma stocks
India should take US pharma complaints seriously
Sun Pharma, Mahindras in India's TOP-10 club
Firms go beyond patent cliff for growth
Why Wockhardt's Waluj facility is under lens